Sanofi, Regeneron anti-PD-1 mAb gets Priority Review

Sanofi (Euronext:SAN; NYSE:SNY) and partner Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said FDA accepted

Read the full 120 word article

User Sign In